Elad Asher: Higher IPF Is Associated with Adverse Outcomes in ICCU
Elad Asher, Head ICCU at Shaare Zedek Medical Center, Jerusalem, shared a post on X about a recent article he and his colleagues co-authored, published in Thrombosis and Haemostasis, adding:
“Pleased to share our new paper in Thrombosis and Haemostasis.
In an unselected ICCU cohort, higher immature platelet fraction was independently associated with adverse outcomes, supporting IPF as a readily available risk marker.”
Title: Immature Platelet Fraction as an Independent Marker of Adverse Outcomes in an Intensive Cardiovascular Care Unit
Authors: Elad Asher, Louay Taha, Mohammad Karmi, Akiva Brin, Pierre Sabouret, Mamas A. Mamas, Noam Fink, Ari Naimark, Amjad Abu-Salman, Michael Glikson
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 12, 2026, 17:55Dries De Wolf: Honored to Have Wolfgang Miesbach Comment on Our Latest Research
-
Sep 12, 2026, 17:53Usman Waheed: Introducing the Discovery of the 49th ISBT Blood Group System
-
Sep 12, 2026, 17:51Maria Sabater Lleal: Happy to Share Our Latest Work Exploring the Genetic Determinants of PE in VTE
-
Sep 12, 2026, 17:51Jeff Sternlicht: Why LDL-C and ApoB Remain King of the Hill?
-
Sep 12, 2026, 17:49Kalyan Roy: TRAGS – An Emerging Transfusion Safety Concern
-
Sep 12, 2026, 17:48Jason Fung: What Happened to “Statins Save Lives”?
-
Sep 12, 2026, 17:47Eric Topol: Most Supplements and Vitamins Offer Little Proven Benefit
-
Sep 12, 2026, 17:44Manuel Monreal: Clinical Characteristics, Treatment, and Outcomes in Hispanic vs Caucasian Patients With VTE
-
Sep 12, 2026, 17:43Sidi Mohamed El Amine Benlazar: CPX-351 and Ruxolitinib in Advanced-Phase Myeloproliferative Neoplasms